Stay updated with breaking news from Human Use. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Servier, a global leader in oncology focused on delivering meaningful therapeutic progress for the patients it serves, today announced the FDA...
/PRNewswire/ -- Contrast Media Market in terms of revenue was estimated to be worth $6.3 billion in 2023 and is poised to reach $9.7 billion by 2029, growing...
(RTTNews) - The European Commission has approved Pfizer's (PFE) Velsipity or etrasimod for the treatment of patients 16 years of age and older wit...
Japan's MHLW has granted priority review for Astellas Pharma’s sNDA for PADCEV and KEYTRUDA combination to treat urothelial cancer.
The sNDA for enfortumab vedotin-ejfv plus pembrolizumab in patients with metastatic urothelial cancer has received priority review in Japan.